查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093233

病患來源異質骨移植（PDX）模型市場－2026-2032年全球市場預測

Patient-Derived Xenograft/PDX Model Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，患者來源異質骨移植(PDX) 模型市場將成長至 159133 億美元，複合年成長率為 15.02%。

主要市場統計數據
基準年 2025 5.9744億美元
預計年份：2026年 6.7851億美元
預測年份：2032年 1,591,330,000 美元
複合年成長率 (%) 15.02%

患者來源的異質骨移植模型在精準腫瘤學中越來越重要。

患者來源異質骨移植模型（PDX模型）是透過將新鮮或冷凍保存的患者腫瘤組織移植到免疫力缺乏小鼠體內而建構的臨床前癌症研究平台，與許多傳統的細胞株來源模型相比，它們能更忠實地保留關鍵的組織病理學、基因組學和表現型特徵。因此，PDX模型在癌症治療藥物發現、轉化研究、生物標記檢驗、協作式臨床實驗室設計、抗藥性機制研究和精準醫療流程中發揮著至關重要的作用。隨著癌症治療研發管線越來越依賴能夠反映患者異質性、腫瘤演變、基質交互作用和治療反應模式的臨床預測模型，這一領域的科學意義日益凸顯。推動這項需求的因素包括：全球癌症負擔日益加重、標靶治療和免疫腫瘤聯合治療的日益普及、新一代定序技術的廣泛應用，以及透過更強力的轉化證據來降低後期臨床開發風險的迫切需求。然而，目前的PDX模型面臨許多局限性，例如移植成功率不穩定、開發週期長、動物實驗倫理問題以及免疫系統可重複性有限等。因此，該領域正朝著更加標準化、分子註釋完善、符合倫理規範且電腦驅動的模型生態系統轉型，以支持學術、臨床和生物製藥研究各個領域的可重複決策。

患者來源異種異質骨移植模型部分的變革性變化

目前，PDX模型的發展方向正從獨立的模型生成服務轉向整合腫瘤移植、基因組分析、藥理學、病理學和生物資訊學的轉化腫瘤學平台。研究人員優先考慮具有詳細臨床註釋的模型，包括治療史、分子亞型、組織學類型以及隨時間推移的反應數據。這些屬性增強了模型在患者分層和生物標記主導的藥物發現中的相關性。人源化PDX模型在免疫腫瘤學研究中的重要性日益凸顯，但由於免疫重建、移植物抗宿主疾病風險以及捐贈者差異等因素可能對結果解讀產生影響，其技術複雜性仍然很高。另一個顯著的轉變是利用PDX衍生的類器官、體外藥物篩檢以及相應的體內研究來縮短決策週期，同時保持生物有效性。此外，傳代次數、腫瘤移植率、真實性驗證、品管、基因組漂移和動物福利實踐等方面的報告規範也在不斷統一，從而推動了模型標準化進程。在監管和資助環境下，可重複性、透明度和減少不必要的動物實驗日益受到重視，促使實驗室採用精心論證的研究設計，並在適當情況下整合其他替代方法。這些變化共同推動PDX模型從探索性工具轉變為以證據為基礎的轉化系統，與精準腫瘤學和臨床驅動療法的開發相契合。

人工智慧對PDX模型研究的累積影響。

人工智慧 (AI) 正日益重塑 PDX 模型開發，顯著提升轉化腫瘤學研究的速度、可重複性和可解釋性。 AI 驅動的影像分析能夠量化人源化系統中的腫瘤形態、壞死、有絲分裂活性、免疫細胞模式以及治療相關的組織學變化，其一致性遠超人工審核，從而支持數位病理工作流程。機器學習模型也被用於整合多組體學資料集、藥物反應結果、臨床註釋和腫瘤生長動態，以識別預測性生物標記並確定治療組合的優先順序。在研究設計中，AI 可根據分子特徵、腫瘤類型和先前治療史，幫助選擇最相關的 PDX 隊列，從而提高動物利用效率，並更好地與臨床假設相符。利用自然語言處理技術，可以在隱私和管治框架允許的範圍內，從病理報告和臨床記錄中提取結構化訊息，以增強模型註釋。然而，人工智慧的應用需要高品質的資料管治、標準化的元資料、透明的模型檢驗、偏差緩解以及對病患​​來源資訊的安全處理。最具意義的影響並非來自黑箱自動化，而是來自可解釋的、基於生物學原理的、並經過獨立資料集檢驗的人工智慧系統。結合穩健的實驗設計，人工智慧可以提升PDX模型的轉化價值，同時支持符合倫理且有效率的腫瘤學研究。

亞太地區、北美地區、歐洲地區和新興地區的關鍵區域洞察

隨著癌症發生率上升、生物醫學領域投資增加以及精準醫療計畫在主要經濟體的擴展，亞太地區正成為PDX模型研究的關鍵區域。中國、日本、韓國、印度、澳洲和東協的研究中心正在加強腫瘤生物生物銀行、分子標靶。美國和加拿大受益於完善的倫理審查體系和綜合癌症中心，這些都為建立臨床註釋模型提供了支持。在拉丁美洲，儘管基礎設施的差異和資金限制影響了PDX模型的應用，但巴西和墨西哥正透過癌症研究機構以及對針對特定人群的腫瘤生物學日益成長的興趣發揮著重要作用，從而推動了更具選擇性的進展。在歐洲，監管和科學界高度重視可重複性、動物福利和癌症合作研究，歐盟正積極推動跨境標準、生物樣本庫管治和數據協調的發展。在中東，癌症治療現代化、基因組醫學計畫和研究能力投資方面均取得了進展，尤其是在海灣合作理事會（GCC）成員國，精準腫瘤學計畫的發展日益成長，對先進的臨床前平台的需求也隨之增加。在非洲，癌症登記系統的發展、病理學領域的能力建設以及針對特定區域癌症類型的合作，正在湧現出新的機會。然而，PDX模型的廣泛應用仍與生物銀行、低溫運輸物流、倫理管治以及對專業動物設施的投資密切相關。在所有地區，只有將臨床註釋、分子譜分析、生物樣本庫品質和監管監督結合，PDX模型的應用才能發揮最大效用。

深入分析東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的研究生態系統。

在東協，隨著成員國在生物醫學研究、腫瘤診斷和臨床試驗領域的參與度不斷提高，PDX模型生態系統的重要性日益凸顯，為研究特定人群的癌症模式和區域生物樣本庫的建設創造了機會。海灣合作理事會（GCC）正透過國家衛生轉型計畫、癌症醫療基礎設施的擴建以及對基因組醫學的投資來鞏固其地位，並在專業機構和倫理框架的支持下，為包括PDX模型在內的轉化腫瘤學平台奠定基礎。歐盟在標準制定、研究合作、動物福利管治和資料保護方面發揮核心作用，並對患者來源腫瘤模型的收集、註釋、共用和檢驗方法的製定具有重大影響。金磚國家（中國、印度、巴西、俄羅斯和南非）擁有多元化的科學基礎和患者群體，為研究不同遺傳、環境和醫療背景下的腫瘤異質性提供了契機，儘管各國的基礎設施成熟度有所不同。七國集團（G7）憑藉其先進的腫瘤研究體系、完善的資金機制、豐富的監管經驗以及成熟的學術和臨床網路，仍然擁有相當大的影響力。這些網路支援將先進的PDX（患者來源腫瘤模型）應用於藥物研發和生物標記檢驗。雖然北約成員國最初並非設計為生物醫學集團，但它們透過囊括眾多生命科學研究蓬勃發展、數據管治能力強、衛生安全優先事項協調一致的國家，間接地支撐著一個具有韌性的生物醫學基礎設施。在這一集團內部，最重要的區別不僅在於地緣政治聯繫，還在於高品質生物樣本庫、標準化的知情同意流程、分子診斷技術、動物福利合規性以及可互通的資料系統。

影響全球PDX模型採用和轉化應用的關鍵國家洞察。

美國憑藉其密集的腫瘤研究網路、先進的分子診斷技術、大規模的臨床實驗室活動以及整合患者組織採集和藥物反應研究的轉化癌症中心，在PDX模型的應用方面發揮著主導作用。加拿大則透過強大的學術癌症計畫、符合倫理的管治以及支持基於臨床洞察的模型開發的人群健康研究做出貢獻。墨西哥和巴西是拉丁美洲的重要貢獻者，它們在癌症生物學研究、不斷擴展的腫瘤基礎設施以及在臨床前系統中反映區域腫瘤多樣性方面擁有許多機會。英國擁有強大的轉化腫瘤學基礎，這得益於生物銀行、基因組學計畫以及臨床研究的整合。德國、法國、義大利和西班牙則透過成熟的生物醫學研究機構、病理學專業知識以及透過歐洲癌症研究網路進行的合作做出貢獻。俄羅斯保持其腫瘤研究能力和科學專長，但國際合作趨勢和基礎設施差異可能會影響跨境模型的取得。中國正快速發展精準醫療、腫瘤生物生物銀行、定序能力和抗癌藥物研發，並在患者來源癌症模型研究方面十分活躍。印度憑藉其龐大且多樣化的患者群體、不斷擴建的癌症中心和日益增強的基因組醫學能力，正日益受到重視，儘管標準化和基礎設施建設仍然是關鍵挑戰。日本以其嚴謹的生物醫學研究、先進的腫瘤學和對分子標靶治療的濃厚興趣而聞名，這為高品質轉化模型的應用提供了支持。澳洲透過其備受讚譽的癌症研究團隊、生物銀行體系和臨床基因組學研究做出貢獻，而韓國則憑藉其強大的生物技術基礎設施、數位醫療能力和在腫瘤領域的積極創新而迅速發展。在這些國家，最佳的PDX模型環境是將病患知情同意、生物組織物流、組織病理學、分子譜分析、動物模型專業知識和臨床相關資料解讀整合到一個統一的工作流程中。

PDX模型開發領導者使用的實用建議。

產業領導者應優先考慮與特定腫瘤適應症、分子亞型和治療機制相符的、具有臨床註釋和分子特徵的PDX模型庫。嚴格的品管應包括腫瘤真實性驗證、與供體腫瘤的組織病理學比較、基因組穩定性監測、傳代追蹤、病原體篩檢以及移植狀態的透明記錄。各機構應加強醫院、生物樣本庫、病理科、定序實驗室、動物設施和計算生物學團隊之間的合作，以縮短從組織採集到模型建構的延遲時間。在免疫腫瘤學計畫中，領導者應仔細評估哪種模型最適合應對科學挑戰：人源化PDX模型、同源模型、類器官或整合的多模型策略。倫理領導力至關重要。研究設計應遵循替代、減少和最佳化的原則，並對動物的使用以及在科學上適當的情況下引入體外或In Silico工具提供明確的依據。資料策略也應受到同等重視，其中包括統一的元元資料、受隱私保護的臨床註釋、可互通的資料庫以及人工智慧賦能的資料集。決策者還應透過使用標準化方案、獨立的檢驗隊列和預先定義的反應標準來提高研究結果的可重複性。最後，PDX模型計畫不應被視為孤立的實驗，而應被視為更廣泛的轉化證據框架的一部分，確保其研究結果與生物標記策略、患者分層、臨床實驗室設計和治療方案決策相聯繫。

基於檢驗的轉化腫瘤學證據的調查方法

本執行摘要採用二手調查方法撰寫，重點關注檢驗的科學、監管和行業相關資訊來源。該方法包括同行評審的腫瘤學和轉化醫學文獻、公共衛生和癌症研究出版物、臨床前研究和動物福利監管指南、癌症研究網路發布的信息，以及對生物生物銀行、病理學、基因組學和患者來源模型開發方面已記錄的最佳實踐的回顧。分析著重於有關應用促進因素、技術趨勢、區域能力、倫理考慮和營運障礙的定性證據，同時有意排除市場規模、市場佔有率和預測。透過比較來自多個可靠資訊來源類別的見解進行交叉檢驗，這些來源包括學術期刊、臨床研究框架、官方癌症統計數據以及實驗室實踐和動物研究管治的認證標準。特別強調可重複性、資料完整性、知情同意、病患隱私、模型表徵和轉化相關性。研究結果在說明部分進行了總結，旨在為參與癌症藥物發現、生物標記開發、精準醫療和轉化癌症研究的相關人員提供策略決策支援。

結論：PDX模型是通往精準腫瘤學的戰略橋樑。

患者來源的異質骨移植模型在精準腫瘤學研究中仍然至關重要，因為它們保留了腫瘤的臨床相關生物學特徵，並支持在生物複雜的系統中評估治療反應。當有完善的臨床註釋、分子譜分析、嚴格的品管和符合倫理的動物實驗實踐作為支撐時，其價值才能最大化。這一領域正在發展成為一個整合平台，將PDX模型與類器官、數位病理學、多體學、人源化系統和人工智慧相結合，旨在提高轉化研究的可信度並減少癌症開發過程中的低效環節。區域和國家層面的部署將繼續取決於癌症研究基礎設施、生物銀行的成熟度、基因組醫學能力、專業的動物實驗設施以及患者來源數據和組織的管治框架。對於產業領導者而言，成功的關鍵在於建構一個可重複、人工智慧賦能且具有臨床意義的PDX模型生態系統，將生物複雜性轉化為可操作的腫瘤學見解。透過將 PDX 模型定位為更廣泛的證據生成策略的一部分，研究人員可以更有效地支持生物標記發現、治療優先排序和精準醫學的進步，而不會過度依賴任何單一的臨床前平台。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 病人異質骨移植模型市場：依類型分類

  • 小鼠模型
  • 大鼠模型

第8章：病人異質骨移植模型市場：依腫瘤類型分類

  • 消化器官系統
  • 婦科
  • 血液系統惡性腫瘤
  • 呼吸系統
  • 泌尿器官系統

第9章：病人異質骨移植模型市場：依研究類型分類

  • Ex-vivo
  • In-vitro
  • In-vivo

第10章：病人異質骨移植模型市場：依移植方法分類

  • 異位
  • 同域
  • 皮下

第11章：病人異質骨移植模型市場：按應用分類

  • 基礎癌症研究
  • 生物標記發現
  • 基因組和分子研究
  • 個人化醫療
  • 臨床前藥物評價
  • 腫瘤微環境分析

第12章：病患異質骨移植模型市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：病患異質骨移植模式市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 病人來源異質骨移植模型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abnova Corporation
  • Altogen Labs
  • Biocytogen
  • BioDuro LLC
  • BioReperia AB
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Animodel
  • Creative Biolabs
  • Crown Bioscience by JSR Corporation
  • EPO Berlin-Buch GmbH
  • GemPharmatech Co. Ltd.
  • Genesis Drug Discovery & Development
  • Hera Biolabs
  • HOIST Co.,Ltd.
  • InnoSer
  • Inotiv, Inc.
  • Laboratory Corporation of America Holdings
  • LIDE Shanghai BIoTech, Ltd
  • Mediford Corporation（PHC Holdings Corporation）
  • Oncodesign Services
  • Shanghai ChemPartner
  • Shanghai Medicilon Inc.
  • TheraIndx Lifesciences Pvt. Ltd.
  • Urosphere SAS
  • WuXi AppTec Co., Ltd.
  • Xentech
Product Code: MRR-FF1601152744

The Patient-Derived Xenograft/PDX Model Market is projected to grow by USD 1,591.33 million at a CAGR of 15.02% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 597.44 million
Estimated Year [2026] USD 678.51 million
Forecast Year [2032] USD 1,591.33 million
CAGR (%) 15.02%

Patient-Derived Xenograft Models Move Toward Precision Oncology Relevance

Patient-derived xenograft (PDX) models are preclinical cancer research platforms created by implanting fresh or cryopreserved patient tumor tissue into immunodeficient mice, preserving key histopathologic, genomic, and phenotypic characteristics more faithfully than many conventional cell-line-derived models. This makes PDX models highly relevant for oncology drug discovery, translational research, biomarker validation, co-clinical trial design, resistance-mechanism studies, and precision medicine workflows. The field is gaining scientific importance as oncology pipelines increasingly depend on clinically predictive models that can reflect interpatient heterogeneity, tumor evolution, stromal interactions, and therapy response patterns. Demand is being shaped by the rising global cancer burden, broader adoption of targeted therapies and immuno-oncology combinations, increased use of next-generation sequencing, and the need to de-risk late-stage clinical development through stronger translational evidence. At the same time, the PDX model landscape is constrained by engraftment variability, long model-development timelines, ethical expectations around animal use, and limitations in immune-system representation. As a result, the sector is moving toward more standardized, molecularly annotated, ethically governed, and computationally enabled model ecosystems that can support reproducible decision-making across academic, clinical, and biopharmaceutical research.

Transformative Shifts in the Patient-Derived Xenograft Model Landscape

The PDX model landscape is undergoing a shift from model generation as a standalone service toward integrated translational oncology platforms that combine tumor engraftment, genomic profiling, pharmacology, pathology, and bioinformatics. Researchers are prioritizing models with deep clinical annotation, including treatment history, molecular subtype, histology, and longitudinal response data, because these attributes improve relevance for patient stratification and biomarker-driven drug development. Humanized PDX models are becoming increasingly important for immuno-oncology studies, although technical complexity remains high because immune reconstitution, graft-versus-host risks, and donor variability can affect interpretation. Another major shift is the use of PDX-derived organoids, ex vivo drug screening, and matched in vivo studies to shorten decision cycles while preserving biological relevance. Standardization is also advancing through harmonized reporting of passage number, tumor take rate, authentication, quality control, genomic drift, and animal welfare practices. Regulatory and funding environments increasingly emphasize reproducibility, transparency, and reduction of unnecessary animal use, pushing laboratories toward carefully justified study designs and integrated alternatives where appropriate. Collectively, these shifts are transforming PDX models from exploratory tools into evidence-rich translational systems aligned with precision oncology and clinically informed therapeutic development.

Cumulative Impact of Artificial Intelligence on PDX Model Research

Artificial intelligence is increasingly reshaping PDX model development by improving the speed, reproducibility, and interpretability of translational oncology research. AI-enabled image analysis can support digital pathology workflows by quantifying tumor morphology, necrosis, mitotic activity, immune-cell patterns in humanized systems, and treatment-related histologic changes with greater consistency than manual review alone. Machine learning models are also being applied to integrate multi-omics datasets, drug-response results, clinical annotations, and tumor-growth kinetics to identify predictive biomarkers and prioritize therapeutic combinations. In study design, AI can help select the most relevant PDX cohorts based on molecular features, tumor type, and prior therapy exposure, supporting more efficient use of animals and better alignment with clinical hypotheses. Natural language processing can extract structured information from pathology reports and clinical records where permitted by privacy and governance frameworks, strengthening model annotation. However, AI adoption depends on high-quality data governance, standardized metadata, transparent model validation, bias mitigation, and secure handling of patient-derived information. The most meaningful impact will come from AI systems that are explainable, biologically grounded, and validated against independent datasets rather than from black-box automation. When combined with robust experimental design, artificial intelligence can improve the translational value of PDX models while supporting ethical and efficient oncology research.

Key Regional Insights Across Asia-Pacific, North America, Europe, and Emerging Regions

Asia-Pacific is becoming a key region for PDX model research as cancer incidence, biomedical investment, and precision medicine programs expand across major economies. China, Japan, South Korea, India, Australia, and ASEAN research hubs are strengthening tumor biobanking, genomic medicine, and oncology trial infrastructure, supporting broader use of patient-derived tumor models in translational studies. North America remains deeply established in PDX model adoption due to mature oncology research networks, advanced sequencing capacity, strong academic medical centers, and widespread use of molecularly guided clinical trials. The United States and Canada benefit from well-developed ethical review systems and integrated cancer centers that support clinically annotated model generation. Latin America is advancing more selectively, with Brazil and Mexico playing important roles through cancer research institutions and growing interest in population-specific tumor biology, although infrastructure variability and funding constraints influence adoption. Europe demonstrates strong regulatory and scientific emphasis on reproducibility, animal welfare, and collaborative cancer research, with the European Union encouraging cross-border standards, biobanking governance, and data harmonization. The Middle East is investing in oncology care modernization, genomic medicine initiatives, and research capacity, particularly in GCC countries, where precision oncology programs are increasing demand for advanced preclinical platforms. Africa has emerging potential through cancer registry development, pathology capacity building, and collaborations focused on regionally relevant cancer types, but broader PDX model deployment remains linked to investments in biobanking, cold-chain logistics, ethical governance, and specialized animal facilities. Across all regions, adoption is most effective where clinical annotation, molecular profiling, biobank quality, and regulatory oversight converge.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO Research Ecosystems

ASEAN is gaining relevance in the PDX model ecosystem as member countries expand biomedical research, oncology diagnostics, and clinical trial participation, with opportunities tied to population-specific cancer patterns and regional biobank development. The GCC is strengthening its position through national health transformation programs, growing cancer care infrastructure, and investments in genomic medicine, creating a foundation for translational oncology platforms that can include PDX models when supported by specialized facilities and ethical frameworks. The European Union plays a central role in standard-setting, research collaboration, animal welfare governance, and data protection, making it influential in shaping how patient-derived tumor models are collected, annotated, shared, and validated. BRICS countries contribute substantial scientific capacity and diverse patient populations, with China, India, Brazil, Russia, and South Africa offering opportunities to study tumor heterogeneity across varied genetic, environmental, and healthcare contexts, although infrastructure maturity differs by country. The G7 remains highly influential because of advanced oncology research systems, extensive funding mechanisms, regulatory experience, and established academic-clinical networks that support sophisticated PDX applications in drug development and biomarker validation. NATO countries, while not a biomedical bloc by design, include many nations with strong life science research, secure data governance capabilities, and coordinated health-security priorities that can indirectly support resilient biomedical infrastructure. Across these groups, the most important differentiators are not geopolitical alignment alone, but the presence of high-quality biobanks, standardized consent processes, molecular diagnostics, animal welfare compliance, and interoperable data systems.

Key Country Insights Shaping Global PDX Model Adoption and Translational Use

The United States leads in PDX model utilization through dense oncology research networks, advanced molecular diagnostics, large-scale clinical trial activity, and translational cancer centers that integrate patient tissue acquisition with drug-response studies. Canada contributes through strong academic cancer programs, ethical governance, and population health research that supports clinically informed model development. Mexico and Brazil are important Latin American contributors, with opportunities linked to cancer-biology research, growing oncology infrastructure, and the need to represent regional tumor diversity in preclinical systems. The United Kingdom has a strong translational oncology base, supported by biobanking, genomics programs, and clinical research integration, while Germany, France, Italy, and Spain contribute through established biomedical research institutions, pathology expertise, and collaborative European cancer networks. Russia maintains oncology research capacity and scientific expertise, although international collaboration dynamics and infrastructure variability can influence cross-border model access. China has rapidly expanded precision medicine, tumor biobanking, sequencing capacity, and oncology drug development, making it highly active in patient-derived cancer model research. India's relevance is increasing due to its large and diverse patient population, expanding cancer centers, and growing genomic medicine capabilities, though standardization and infrastructure scale-up remain important. Japan is recognized for rigorous biomedical research, advanced oncology care, and strong interest in molecularly targeted therapies, supporting high-quality translational model use. Australia contributes through well-regarded cancer research groups, biobanking frameworks, and clinical-genomic studies, while South Korea is advancing rapidly through strong biotechnology infrastructure, digital health capabilities, and active oncology innovation. Across these countries, the strongest PDX model environments are those that connect patient consent, fresh tissue logistics, histopathology, molecular profiling, animal model expertise, and clinically relevant data interpretation into an integrated workflow.

Actionable Recommendations for Leaders in PDX Model Development

Industry leaders should prioritize clinically annotated, molecularly characterized PDX model repositories that align with specific oncology indications, molecular subtypes, and therapeutic mechanisms. Robust quality control should include tumor authentication, histopathologic comparison with the donor tumor, genomic stability monitoring, passage tracking, pathogen screening, and transparent documentation of engraftment conditions. Organizations should strengthen partnerships among hospitals, biobanks, pathology units, sequencing laboratories, animal facilities, and computational biology teams to reduce delays between tissue collection and model development. For immuno-oncology programs, leaders should carefully evaluate whether humanized PDX models, syngeneic models, organoids, or integrated multi-model strategies best fit the scientific question. Ethical leadership is essential: study designs should follow the principles of replacement, reduction, and refinement, with clear justification for animal use and incorporation of ex vivo or in silico tools where scientifically valid. Data strategy should receive equal attention, including harmonized metadata, privacy-preserving clinical annotation, interoperable databases, and AI-ready datasets. Decision-makers should also invest in reproducibility by using standardized protocols, independent validation cohorts, and predefined response criteria. Finally, PDX model programs should be positioned as part of a broader translational evidence framework rather than as isolated experiments, ensuring that findings connect to biomarker strategy, patient stratification, clinical trial design, and therapeutic portfolio decisions.

Research Methodology Grounded in Verified Translational Oncology Evidence

This executive summary is developed using a secondary research methodology focused on verified scientific, regulatory, and industry-relevant sources. The approach includes review of peer-reviewed oncology and translational medicine literature, public health and cancer research publications, regulatory guidance on preclinical research and animal welfare, publicly available information from cancer research networks, and documented best practices in biobanking, pathology, genomics, and patient-derived model development. The analysis emphasizes qualitative evidence on adoption drivers, technology trends, regional capabilities, ethical considerations, and operational barriers while deliberately excluding market sizing, market share, and forecasting. Cross-validation is performed by comparing findings across multiple credible source categories, including academic publications, clinical research frameworks, public cancer statistics, and recognized standards for laboratory practice and animal research governance. Particular attention is given to reproducibility, data integrity, informed consent, patient privacy, model characterization, and translational relevance. Insights are synthesized into narrative sections to support strategic decision-making for stakeholders involved in oncology drug discovery, biomarker development, precision medicine, and translational cancer research.

Conclusion: PDX Models as a Strategic Bridge to Precision Oncology

Patient-derived xenograft models remain a vital component of precision oncology research because they can preserve clinically relevant tumor biology and support evaluation of therapeutic response in biologically complex systems. Their value is highest when they are supported by strong clinical annotation, molecular profiling, rigorous quality control, and ethically responsible animal research practices. The field is moving toward integrated platforms that combine PDX models with organoids, digital pathology, multi-omics, humanized systems, and artificial intelligence to improve translational confidence and reduce inefficiencies in oncology development. Regional and country-level adoption will continue to depend on cancer research infrastructure, biobanking maturity, genomic medicine capacity, specialized animal facilities, and governance frameworks for patient-derived data and tissue. For industry leaders, success will depend on building reproducible, AI-ready, and clinically aligned PDX model ecosystems that can translate biological complexity into actionable oncology insights. By treating PDX models as part of a broader evidence-generation strategy, researchers can better support biomarker discovery, therapeutic prioritization, and precision medicine advancement without overreliance on any single preclinical platform.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Patient-Derived Xenograft/PDX Model Market, by Type

  • 7.1. Introduction
  • 7.2. Mice Models
  • 7.3. Rat Models

8. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 8.1. Introduction
  • 8.2. Gastrointestinal
  • 8.3. Gynecological
  • 8.4. Hematological
  • 8.5. Respiratory
  • 8.6. Urological

9. Patient-Derived Xenograft/PDX Model Market, by Study Type

  • 9.1. Introduction
  • 9.2. Ex-vivo
  • 9.3. In-vitro
  • 9.4. In-vivo

10. Patient-Derived Xenograft/PDX Model Market, by Implantation Method

  • 10.1. Introduction
  • 10.2. Heterotopic
  • 10.3. Orthotopic
  • 10.4. Subcutaneous

11. Patient-Derived Xenograft/PDX Model Market, by Application

  • 11.1. Introduction
  • 11.2. Basic Cancer Research
  • 11.3. Biomarker Discovery
  • 11.4. Genomic & Molecular Studies
  • 11.5. Personalized Medicine
  • 11.6. Preclinical Drug Evaluation
  • 11.7. Tumor Microenvironment Analysis

12. Patient-Derived Xenograft/PDX Model Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Patient-Derived Xenograft/PDX Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Patient-Derived Xenograft/PDX Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abnova Corporation
  • 16.2. Altogen Labs
  • 16.3. Biocytogen
  • 16.4. BioDuro LLC
  • 16.5. BioReperia AB
  • 16.6. Certis Oncology Solutions
  • 16.7. Champions Oncology, Inc.
  • 16.8. Charles River Laboratories International, Inc.
  • 16.9. Creative Animodel
  • 16.10. Creative Biolabs
  • 16.11. Crown Bioscience by JSR Corporation
  • 16.12. EPO Berlin-Buch GmbH
  • 16.13. GemPharmatech Co. Ltd.
  • 16.14. Genesis Drug Discovery & Development
  • 16.15. Hera Biolabs
  • 16.16. HOIST Co.,Ltd.
  • 16.17. InnoSer
  • 16.18. Inotiv, Inc.
  • 16.19. Laboratory Corporation of America Holdings
  • 16.20. LIDE Shanghai Biotech, Ltd
  • 16.21. Mediford Corporation by PHC Holdings Corporation
  • 16.22. Oncodesign Services
  • 16.23. Shanghai ChemPartner
  • 16.24. Shanghai Medicilon Inc.
  • 16.25. TheraIndx Lifesciences Pvt. Ltd.
  • 16.26. Urosphere SAS
  • 16.27. WuXi AppTec Co., Ltd.
  • 16.28. Xentech

LIST OF FIGURES

  • FIGURE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MICE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MICE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MICE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GYNECOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GYNECOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GYNECOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UROLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UROLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UROLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EX-VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EX-VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EX-VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HETEROTOPIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HETEROTOPIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HETEROTOPIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORTHOTOPIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORTHOTOPIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORTHOTOPIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BASIC CANCER RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BASIC CANCER RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BASIC CANCER RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOMIC & MOLECULAR STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENOMIC & MOLECULAR STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOMIC & MOLECULAR STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRECLINICAL DRUG EVALUATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PRECLINICAL DRUG EVALUATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRECLINICAL DRUG EVALUATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TUMOR MICROENVIRONMENT ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TUMOR MICROENVIRONMENT ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TUMOR MICROENVIRONMENT ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 114. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 132. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 138. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 151. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 157. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 163. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 175. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 187. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 199. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 211. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 217. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 223. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 229. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 231. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025